HM Payson & Co’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-200
| Closed | -$976 | – | 1003 |
|
|
2025
Q1 | $976 | Hold |
200
| – | – | ﹤0.01% | 1003 |
|
|
2024
Q4 | $1.67K | Sell |
200
-50
| -20% | -$437 | ﹤0.01% | 971 |
|
|
2024
Q3 | $2.6K | Hold |
250
| – | – | ﹤0.01% | 949 |
|
|
2024
Q2 | $4.92K | Buy |
250
+200
| +400% | +$4.01K | ﹤0.01% | 890 |
|
|
2024
Q1 | $1.28K | Hold |
50
| – | – | ﹤0.01% | 920 |
|
|
2023
Q4 | $1.38K | Sell |
50
-30
| -38% | -$1.83K | ﹤0.01% | 921 |
|
|
2023
Q3 | $4.86K | Buy |
80
+30
| +60% | +$2.11K | ﹤0.01% | 876 |
|
|
2023
Q2 | $3.29K | Hold |
50
| – | – | ﹤0.01% | 887 |
|
|
2023
Q1 | $3.18K | Hold |
50
| – | – | ﹤0.01% | 893 |
|
|
2022
Q4 | $6.92K | Hold |
50
| – | – | ﹤0.01% | 780 |
|
|
2022
Q3 | $6K | Hold |
50
| – | – | ﹤0.01% | 830 |
|
|
2022
Q2 | $4K | Hold |
50
| – | – | ﹤0.01% | 905 |
|
|
2022
Q1 | $5K | Hold |
50
| – | – | ﹤0.01% | 906 |
|
|
2021
Q4 | $10K | Sell |
50
-27
| -35% | -$6.37K | ﹤0.01% | 857 |
|
|
2021
Q3 | $19K | Buy |
77
+38
| +97% | +$10.9K | ﹤0.01% | 746 |
|
|
2021
Q2 | $16K | Buy |
+39
| New | +$15.4K | ﹤0.01% | 775 |
|
|
2020
Q4 | – | Sell |
-26
| Closed | -$18K | – | 1089 |
|
|
2020
Q3 | $18K | Buy |
+26
| New | +$20.3K | ﹤0.01% | 746 |
|
Other funds holding BLUE
HM Payson & Co's BLUE Position: Q2 2025 in Review
HM Payson & Co sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 200 shares — an estimated $976 sold.
HM Payson & Co first reported a position in BLUE in Q3 2020 and held it in 17 quarters. The position peaked at $19K in Q3 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- HM Payson & Co reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- HM Payson & Co sold 200 bluebird bio shares in Q2 2025, an estimated $976.
- HM Payson & Co first reported a position in bluebird bio in Q3 2020 and held it in 17 quarters.
- HM Payson & Co's bluebird bio position peaked at $19K in Q3 2021.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on HM Payson & Co's 13F filing for Q2 2025, filed 17 Oct 2025.